BRAXIA SCIENTIFIC CORP. (4960) - Net Assets
Based on the latest financial reports, BRAXIA SCIENTIFIC CORP. (4960) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BRAXIA SCIENTIFIC CORP. tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | -68.25% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 19.25 |
BRAXIA SCIENTIFIC CORP. - Net Assets Trend (2021–2023)
This chart illustrates how BRAXIA SCIENTIFIC CORP.'s net assets have evolved over time, based on quarterly financial data. See BRAXIA SCIENTIFIC CORP. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for BRAXIA SCIENTIFIC CORP. (2021–2023)
The table below shows the annual net assets of BRAXIA SCIENTIFIC CORP. from 2021 to 2023. For live valuation and market cap data, see market value of BRAXIA SCIENTIFIC CORP..
| Year | Net Assets | Change |
|---|---|---|
| 2023-03-31 | €1.60 Million ≈ $1.88 Million |
-82.10% |
| 2022-03-31 | €8.96 Million ≈ $10.48 Million |
-43.59% |
| 2021-03-31 | €15.89 Million ≈ $18.58 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BRAXIA SCIENTIFIC CORP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2527579500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €117.63 Million | 7330.45% |
| Total Equity | €1.60 Million | 100.00% |
BRAXIA SCIENTIFIC CORP. Competitors by Market Cap
The table below lists competitors of BRAXIA SCIENTIFIC CORP. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MicroStrategy Incorporated 10.00% Series A Perpetual Stride Preferred Stock
NASDAQ:STRD
|
$570.75K |
|
Xplore Resources Corp
V:XPLR
|
$570.77K |
|
Ireka Corporation Bhd
KLSE:8834
|
$571.89K |
|
Caspian Sunrise plc
LSE:CASP
|
$572.87K |
|
Goldflare Exploration Inc
V:GOFL
|
$564.64K |
|
Bitcoin Fund Unit
TO:QBTC
|
$562.58K |
|
GAMES BOX S.A. ZY-10
F:ZN6
|
$562.53K |
|
Splash Beverage Group Inc
NYSE MKT:SBEV
|
$561.46K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BRAXIA SCIENTIFIC CORP.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 8,962,631 to 1,604,729, a change of -7,357,902 (-82.1%).
- Net loss of 13,141,704 reduced equity.
- New share issuances of 1,264,219 increased equity.
- Other factors increased equity by 4,519,583.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-13.14 Million | -818.94% |
| Share Issuances | €1.26 Million | +78.78% |
| Other Changes | €4.52 Million | +281.64% |
| Total Change | €- | -82.10% |
Book Value vs Market Value Analysis
This analysis compares BRAXIA SCIENTIFIC CORP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.02x to 0.33x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-03-31 | €0.09 | €0.00 | x |
| 2022-03-31 | €0.05 | €0.00 | x |
| 2023-03-31 | €0.01 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BRAXIA SCIENTIFIC CORP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -818.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -697.48%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 2.42x
- Recent ROE (-818.94%) is below the historical average (-504.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -559.04% | -8809.07% | 0.05x | 1.16x | €-90.42 Million |
| 2022 | -135.39% | -815.93% | 0.13x | 1.30x | €-13.03 Million |
| 2023 | -818.94% | -697.48% | 0.49x | 2.42x | €-13.30 Million |
Industry Comparison
This section compares BRAXIA SCIENTIFIC CORP.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,435,678,106
- Average return on equity (ROE) among peers: -30.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BRAXIA SCIENTIFIC CORP. (4960) | €- | -559.04% | N/A | $566.56K |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $179.82 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.10 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.60 Million | -113.13% | 0.23x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $20.05 Billion |
About BRAXIA SCIENTIFIC CORP.
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery metho… Read more